Abstract: The present invention encompasses pet food compositions that include one or more probiotic microorganisms, which are useful to improve the health of companion animals. For example, the invention encompasses pet food compositions including a probiotic, for example, Lactobacillus, Bifidobacterium and Streptococcus (Enterococcus). The present invention also encompasses the preparation of pet food compositions including one or more probiotic microorganisms intended for methods of maintaining or improving pet health through feeding a pet a pet food composition including the probiotic microorganism.

Abstract: Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and ?-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).

Abstract: Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and ?-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).

Abstract: The invention encompasses pet food composition that delivers a slow, sustained-release amount of lipoic acid or a salt thereof when fed orally to a companion animal. The invention also encompasses methods of manufacture and use of the compositions.

Abstract: The present invention encompasses pet food compositions that include one or more probiotic microorganisms, which are useful to improve the health of companion animals. For example, the invention encompasses pet food compositions including a probiotic, for example, Lactobacillus, Bifidobacterium and Streptococcus (Enterococcus). The present invention also encompasses the preparation of pet food compositions including one or more probiotic microorganisms intended for methods of maintaining or improving pet health through feeding a pet a pet food composition including the probiotic microorganism.

Abstract: Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and ?-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).

Abstract: A method for preparing compositions, comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and ?-linoleic acid (ALA), that are administered to felines for treating feline inflammatory bowel disease (IBD).

Abstract: Compositions comprising eicosapentaenoic acid and docosahexaenoic acid in a ratio of from 1.2 to 2 are administered to felines to treat feline inflammatory bowel disease.

Abstract: A composition suitable for mammalian oral ingestion in a mammal having GI tract inflammation comprising an anti-diarrhea effective amount of glutamine, fermentable fiber(s), antioxidant(s), and omega-3 fatty acid(s).

Abstract: Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and ?-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).

Abstract: Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and ?-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).

Abstract: A method for reducing the amount of a proinflammatory substance present at an elevated level in animal tissue or body fluid by orally administering to the animal a proinflammatory substance reducing amount of a composition comprising at least one omega-3 fatty acid. The method is useful for reducing inflammation caused by elevated levels of proinflammatory substances including inflammation associated with an oral condition.

Abstract: A method for reducing the quantity of Desulfovibrio and/or Helicobacter spp. in the GI tract of a companion pet which comprises orally administering to the said pet a Desulfovibrio and/or Helicobacter spp. reducing quantity of a fiber or other component.

Abstract: The present invention provides a method for increasing the intestinal (lymphatic) absorption, cellular concentration, biliary secretion, hepatic storage, and/or liver concentration of a fat soluble vitamin in a post-menopausal woman. The method comprises orally administering to a post-menopausal woman in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine. The L-carnitine enhances the antioxidant defense mechanism and lowers the risk of certain degenerative diseases, such as coronary heart disease, age-related macular degeneration, osteoporosis, cancer, and Alzheimer's, in post-menopausal women. The invention also provides a method for increasing the intestinal absorption of a fat soluble vitamin in an animal. The method comprises orally administering to the animal in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine.

Abstract: Applicants have discovered that L-carnitine increases the intestinal (lymphatic) absorption of fat soluble vitamins, such as vitamins A, D, and E, in post-menopausal women. As a result, L-carnitine enhances the antioxidant defense mechanism and lowers the risk of certain degenerative diseases, such as coronary heart disease, age-related macular degeneration, osteoporosis, cancer, and Alzheimer's, in post-menopausal women. The present invention provides a method for increasing the intestinal absorption, cellular concentration, biliary secretion, hepatic storage, and/or liver concentration of a fat soluble vitamin in a post-menopausal woman. The method comprises orally administering to a post-menopausal woman in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine. The invention also provides a method for increasing the intestinal absorption of a fat soluble vitamin in an animal.